Halozyme Therapeutics, Inc. filings document the company's drug-delivery business, royalty-based collaboration model, governance actions and capital-market disclosures. 8-K reports cover financial results and guidance, executive officer appointments and compensation arrangements, bylaw amendments, and annual meeting voting results.
Proxy materials describe board elections, executive compensation, equity awards, auditor ratification and stockholder voting mechanics. Filings also provide formal disclosure around ENHANZE, Hypercon and Surf Bio technology portfolio updates, partnered commercial products, and acquisition-related operating updates when reported by the company.
Halozyme Therapeutics, Inc. reported third-quarter 2026 revenue of $493.0 million, compared with $354.3 million in 2025, and net income of $247.0 million, versus $175.2 million. For the nine months ended September 30, revenue was $1,350.7 million and net income was $627.0 million, compared with $944.8 million and $458.5 million, respectively, in 2025.
Net cash provided by operating activities for the nine months ended September 30 was $679.2 million, and cash and cash equivalents were $1.030 billion as of September 30, 2026. In September, Halozyme completed the sale of $1.50 billion of 1.50% convertible senior notes due 2033, receiving approximately $1.47 billion in net proceeds; holders could not convert the notes as of September 30. The company reported $55.2 million of stockholders’ deficit at quarter-end. A partner was evaluating whether to return a target, with a decision expected by February 2027; a return without an alternative target with similar future cash flows could result in a material interim impairment charge.
Halozyme Therapeutics, Inc. reported third-quarter 2026 revenue of $493.0 million, up 39% from $354.3 million a year earlier. Royalty revenue rose 44% to $341.0 million from $236.0 million. Net income was $247.0 million versus $175.2 million, and GAAP diluted earnings per share were $2.01 versus $1.43.
The company raised 2026 guidance to $1.860–$1.925 billion in total revenue, $1.235–$1.255 billion in royalty revenue, $1.240–$1.290 billion in adjusted EBITDA and $8.75–$9.05 per share in non-GAAP diluted EPS. The EBITDA and EPS outlook includes approximately $60 million of Hypercon and Aerocon investments; EPS guidance excludes potential future share repurchases.
Halozyme completed its $1.5 billion convertible notes and reported $400 million of 2026 share repurchases. Three partner programs advanced into Phase 1, bringing products in development to twelve. In October, the specialized Dutch patent court in The Hague found Merck Sharp & Dohme B.V. infringed one MDASE patent and ordered it to refrain from specified Keytruda Qlex activities in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands.
HALO’s President and CEO Helen Torley exercised options for 20,000 common shares on each of October 6, 7 and 8, 2026, at an exercise price of $18.4100 per share, acquiring 60,000 shares in total. On those same dates, she sold 60,000 common shares; reported weighted-average sale prices included 2,300 shares at $107.9020 on October 6, 8,600 at $111.0310 on October 7, and 11,900 at $109.9950 on October 8. The exercises and sales were made under a written Rule 10b5-1 trading plan adopted December 3, 2025. The options were granted February 14, 2018, and their reported expiration date is February 14, 2028.
Halozyme Therapeutics, Inc. director Bernadette Connaughton received an annual grant of 3,796 restricted stock units on May 5, 2026. Each RSU represents the right to receive one common share. The amendment corrects the earlier report’s award count from 6,796 to 3,796 and revises securities beneficially owned following the transaction to 42,294.
Halozyme Therapeutics, Inc. director James M. Daly was granted two compensation awards on October 1, 2026: 1,169 restricted stock units and 1,775 options to purchase common stock, with an exercise price of $106.94 per share. The restricted stock units are scheduled to vest on the date of the Issuer’s 2027 annual meeting, and the options vest in full on that date.
Halozyme Therapeutics, Inc. (HALO) director Matthew L. Posard sold 5,230 common shares on October 1, 2026, in four transactions: 730 shares at a weighted average price of $107.168 per share, 3,300 at $108.454, 1,100 at $109.569 and 100 at $110.040. The sales were made under a written Rule 10b5-1 trading plan adopted June 15, 2026.
Halozyme Therapeutics (HALO) elected James Daly to its Board of Directors on September 28, 2026. His term is in the director class ending at the 2029 annual meeting, and he was not initially assigned to a Board committee. Daly will receive compensation under the program for non-employee directors, which currently includes cash retainers for Board and committee service, restricted stock and stock option awards. The company stated that no arrangements or understandings led to his election and that there are no related person transactions between the company and Daly.
HALOZYME THERAPEUTICS, INC. (HALO) completed a private offering of $1,500.0 million aggregate principal amount of 1.50% Convertible Senior Notes due 2033, including $200.0 million from the initial purchasers’ option, issued under an indenture with The Bank of New York Mellon Trust Company, N.A. as trustee.
The company received $1,471.1 million of net proceeds, using about $187.5 million to enter into capped call transactions and expecting to use portions to repurchase $151.7 million of its 0.25% 2027 notes and $220.0 million of its 1.00% 2028 notes, with remaining proceeds earmarked for general corporate purposes and potential future note repurchases. The notes bear 1.50% interest, are convertible at an initial rate of 7.1509 shares per $1,000 (conversion price about $139.84), and are subject to various conversion, redemption, repurchase and default provisions. Capped call transactions, with an initial cap of $208.39 per share (about 90.0% above the September 17, 2026 close), are intended to reduce potential dilution or offset cash payments above principal upon conversion.
Halozyme Therapeutics, Inc. (HALO) priced an upsized private offering of $1.3 billion aggregate principal amount of 1.50% convertible senior notes due 2033, with an additional $200 million option for initial purchasers. The notes are senior unsecured, pay 1.50% interest semi-annually, and are offered only to qualified institutional buyers.
The notes have an initial conversion rate of 7.1509 shares per $1,000, equivalent to a conversion price of $139.84, a 27.5% premium to the $109.68 closing stock price on September 17, 2026. Halozyme expects net proceeds of about $1.275 billion (or $1.471 billion if the option is fully exercised).
The company plans to use approximately $162.5 million of proceeds to enter into capped call transactions with a cap price of about $208.39, and to repurchase about $151.7 million of 2027 notes and $220.0 million of 2028 notes for total cash costs of roughly $217.0 million and $435.5 million, respectively. Remaining proceeds are earmarked for general corporate purposes and potential additional note repurchases.